210 related articles for article (PubMed ID: 21205085)
1. Disrupted plasma membrane localization of equilibrative nucleoside transporter 2 in the chemoresistance of human pancreatic cells to gemcitabine (dFdCyd).
Nishio R; Tsuchiya H; Yasui T; Matsuura S; Kanki K; Kurimasa A; Hisatome I; Shiota G
Cancer Sci; 2011 Mar; 102(3):622-9. PubMed ID: 21205085
[TBL] [Abstract][Full Text] [Related]
2. Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer.
Ferrandina G; Mey V; Nannizzi S; Ricciardi S; Petrillo M; Ferlini C; Danesi R; Scambia G; Del Tacca M
Cancer Chemother Pharmacol; 2010 Mar; 65(4):679-86. PubMed ID: 19639316
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells.
Nakano Y; Tanno S; Koizumi K; Nishikawa T; Nakamura K; Minoguchi M; Izawa T; Mizukami Y; Okumura T; Kohgo Y
Br J Cancer; 2007 Feb; 96(3):457-63. PubMed ID: 17224927
[TBL] [Abstract][Full Text] [Related]
4. Contribution of thymidylate synthase to gemcitabine therapy for advanced pancreatic cancer.
Komori S; Osada S; Mori R; Matsui S; Sanada Y; Tomita H; Tokuyama Y; Takahashi T; Yamaguchi K; Yoshida K
Pancreas; 2010 Nov; 39(8):1284-92. PubMed ID: 20944490
[TBL] [Abstract][Full Text] [Related]
5. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.
Giovannetti E; Del Tacca M; Mey V; Funel N; Nannizzi S; Ricci S; Orlandini C; Boggi U; Campani D; Del Chiaro M; Iannopollo M; Bevilacqua G; Mosca F; Danesi R
Cancer Res; 2006 Apr; 66(7):3928-35. PubMed ID: 16585222
[TBL] [Abstract][Full Text] [Related]
6. MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells.
Rajabpour A; Afgar A; Mahmoodzadeh H; Radfar JE; Rajaei F; Teimoori-Toolabi L
Cancer Chemother Pharmacol; 2017 Oct; 80(4):765-775. PubMed ID: 28887583
[TBL] [Abstract][Full Text] [Related]
7. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma.
Maréchal R; Bachet JB; Mackey JR; Dalban C; Demetter P; Graham K; Couvelard A; Svrcek M; Bardier-Dupas A; Hammel P; Sauvanet A; Louvet C; Paye F; Rougier P; Penna C; André T; Dumontet C; Cass CE; Jordheim LP; Matera EL; Closset J; Salmon I; Devière J; Emile JF; Van Laethem JL
Gastroenterology; 2012 Sep; 143(3):664-674.e6. PubMed ID: 22705007
[TBL] [Abstract][Full Text] [Related]
8. Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2',2'-difluorodeoxycytidine- induced cytotoxicity.
García-Manteiga J; Molina-Arcas M; Casado FJ; Mazo A; Pastor-Anglada M
Clin Cancer Res; 2003 Oct; 9(13):5000-8. PubMed ID: 14581375
[TBL] [Abstract][Full Text] [Related]
9. The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family.
Skrypek N; Duchêne B; Hebbar M; Leteurtre E; van Seuningen I; Jonckheere N
Oncogene; 2013 Mar; 32(13):1714-23. PubMed ID: 22580602
[TBL] [Abstract][Full Text] [Related]
10. Curcumin and its cyclohexanone analogue inhibited human Equilibrative nucleoside transporter 1 (ENT1) in pancreatic cancer cells.
Revalde JL; Li Y; Wijeratne TS; Bugde P; Hawkins BC; Rosengren RJ; Paxton JW
Eur J Pharmacol; 2017 May; 803():167-173. PubMed ID: 28365185
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer.
Ohhashi S; Ohuchida K; Mizumoto K; Fujita H; Egami T; Yu J; Toma H; Sadatomi S; Nagai E; Tanaka M
Anticancer Res; 2008; 28(4B):2205-12. PubMed ID: 18751396
[TBL] [Abstract][Full Text] [Related]
12. Human equilibrative nucleoside transporter 1, as a predictor of 5-fluorouracil resistance in human pancreatic cancer.
Tsujie M; Nakamori S; Nakahira S; Takahashi Y; Hayashi N; Okami J; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
Anticancer Res; 2007; 27(4B):2241-9. PubMed ID: 17695509
[TBL] [Abstract][Full Text] [Related]
13. Fluorouracil uptake in triple-negative breast cancer cells: Negligible contribution of equilibrative nucleoside transporters 1 and 2.
Noguchi S; Takagi A; Tanaka T; Takahashi Y; Pan X; Kibayashi Y; Mizokami R; Nishimura T; Tomi M
Biopharm Drug Dispos; 2021 Mar; 42(2-3):85-93. PubMed ID: 33426680
[TBL] [Abstract][Full Text] [Related]
14. Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells.
Mori R; Ishikawa T; Ichikawa Y; Taniguchi K; Matsuyama R; Ueda M; Fujii Y; Endo I; Togo S; Danenberg PV; Shimada H
Oncol Rep; 2007 May; 17(5):1201-5. PubMed ID: 17390066
[TBL] [Abstract][Full Text] [Related]
15. ST6Gal-I sialyltransferase promotes chemoresistance in pancreatic ductal adenocarcinoma by abrogating gemcitabine-mediated DNA damage.
Chakraborty A; Dorsett KA; Trummell HQ; Yang ES; Oliver PG; Bonner JA; Buchsbaum DJ; Bellis SL
J Biol Chem; 2018 Jan; 293(3):984-994. PubMed ID: 29191829
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine sensitivity-related mRNA expression in endoscopic ultrasound-guided fine-needle aspiration biopsy of unresectable pancreatic cancer.
Ashida R; Nakata B; Shigekawa M; Mizuno N; Sawaki A; Hirakawa K; Arakawa T; Yamao K
J Exp Clin Cancer Res; 2009 Jun; 28(1):83. PubMed ID: 19531250
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine chemoresistance in pancreatic cancer: molecular mechanisms and potential solutions.
Andersson R; Aho U; Nilsson BI; Peters GJ; Pastor-Anglada M; Rasch W; Sandvold ML
Scand J Gastroenterol; 2009; 44(7):782-6. PubMed ID: 19214867
[TBL] [Abstract][Full Text] [Related]
18. Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells.
Hagmann W; Jesnowski R; Löhr JM
Neoplasia; 2010 Sep; 12(9):740-7. PubMed ID: 20824050
[TBL] [Abstract][Full Text] [Related]
19. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma.
Spratlin J; Sangha R; Glubrecht D; Dabbagh L; Young JD; Dumontet C; Cass C; Lai R; Mackey JR
Clin Cancer Res; 2004 Oct; 10(20):6956-61. PubMed ID: 15501974
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and in vitro evaluation of novel lipophilic monophosphorylated gemcitabine derivatives and their nanoparticles.
Lansakara-P DS; Rodriguez BL; Cui Z
Int J Pharm; 2012 Jun; 429(1-2):123-34. PubMed ID: 22425885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
